DNA methylotype analysis in colorectal cancer

Oncology Reports

Volumn 20, Issue 4, 2008, Pages 921-927

  Yu, Jinsheng ^a,b,c   Freimuth, Robert R ^a,b,c   Culverhouse, Robert ^a,c   Marsh, Sharon ^a,b,c   Watson, Mark A ^a,b,c   McLeod, Howard L ^a,b,c,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b USA

^c CREATE Pharmacogenetic Research Network   (United States)

^d UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Colorectal cancer; DNA methylation; Methylotype; Pyrosequencing

Indexed keywords

BISULFITE; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DIHYDROPYRIMIDINE DEHYDROGENASE; DNA; PROTEIN MLH1; RNA;

ADULT; AGED; ARTICLE; COLON CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DNA SEQUENCE; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RNA, NEOPLASM;

EID: 54949098442     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or_00000092     Document Type: Article

References (23)

1. Kim YH, Petko Z, Dzieciatkowski S, Lin L, Ghiassi M, Stain S, Chapman WC, Washington MK, Willis J, Markowitz SD and Grady WM: CpG island methylation of genes accumulates during the adenoma progression step of the multistep pathogenesis of colorectal cancer. Genes Chromosomes Cancer 45: 781-789, 2006.
2. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
3. Goel A, Nagasaka T, Arnold CN, Inoue T, Hamilton C, Niedzwiecki D, Compton C, Mayer RJ, Goldberg R, Bertagnolli MM and Boland CR: The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer. Gastroenterology 132: 127-138, 2007.
4. Nuovo GJ, Nakagawa H, Sotamaa K and Chapelle Ade L: Hypermethylation of the MLH1 promoter with concomitant absence of transcript and protein occurs in small patches of crypt cells in unaffected mucosa from sporadic colorectal carcinoma. Diagn Mol Pathol 15: 17-23, 2006.
5. Kim BN, Yamamoto H, Ikeda K, Damdinsuren B, Sugita Y, Ngan CY, Fujie Y, Ogawa M, Hata T, Ikeda M, Ohue M, Sekimoto M, Monden T, Matsuura N and Monden M: Methylation and expression of p16INK4 tumor suppressor gene in primary colorectal cancer tissues. Int J Oncol 26: 1217-1226, 2005.
6. Ezzeldin HH, Lee AM, Mattison LK and Diasio RB: Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res 11: 8699-8705, 2005.
7. Yegnasubramanian S, Kowalski J, Gonzalgo ML, Zahurak M, Piantadosi S, Walsh PC, Bova GS, De Marzo AM, Isaacs WB and Nelson WG: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. Cancer Res 64: 1975-1986, 2004.
8. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C and Sidransky D: Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 4: 1-8, 2006.
9. Brakensiek K, Wingen LU, Langer F, Kreipe H and Lehmann U: Quantitative high-resolution CpG island mapping with Pyrosequencing reveals disease-specific methylation patterns of the CDKN2B gene in myelodysplastic syndrome and myeloid leukemia. Clin Chem 53: 17-23, 2007.
10. Yang I, Park IY, Jang SM, Shi LH, Ku HK and Park SR: Rapid quantification of DNA methylation through dNMP analysis following bisulfite-PCR. Nucleic Acids Res 34: e61,2006.
11. Marsh S, King CR, Garsa AA and McLeod HL: Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol 311: 97-114, 2005.
12. Yu J, Shannon WD, Watson MA and McLeod HL: Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 11: 2053-2062, 2005.
13. Yu J, Mallon MA, Zhang W, Freimuth RR, Marsh S, Watson MA, Goodfellow PJ and McLeod HL: DNA repair pathway profiling and microsatellite instability in colorectal cancer. Clin Cancer Res 12: 5104-5111, 2006.
14. Yu J, McLeod HL, Ezzeldin HH and Diasio RB: Methylation of the DPYD promoter and dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res 12: 3864, 2006.
15. Brena RM, Huang TH and Plass C: Quantitative assessment of DNA methylation: potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med 84: 365-377, 2006.
16. Shaw RJ, Liloglou T, Rogers SN, Brown JS, Vaughan ED, Lowe D, Field JK and Risk JM: Promoter methylation of P16, RARbeta, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. Br J Cancer 94: 561-568, 2006.
17. Taylor KH, Pena-Hernandez KE, Davis JW, Arthur GL, Duff DJ, Shi H, Rahmatpanah FB, Sjahputera O and Caldwell CW: Large-scale CpG methylation analysis identifies novel candidate genes and reveals methylation hotspots in acute lymphoblastic leukemia. Cancer Res 67: 2617-2625, 2007.
18. Model F, Osborn N, Ahlquist D, Gruetzmann R, Molnar B, Sipos F, Galamb O, Pilarsky C, Saeger HD, Tulassay Z, Hale K, Mooney S, Lograsso J, Adorjan P, Lesche R, Dessauer A, Kleiber J, Porstmann B, Sledziewski A and Lofton-Day C: Identification and validation of colorectal neoplasia-specific methylation markers for accurate classification of disease. Mol Cancer Res 5: 153-163, 2007.
19. Laird PW: The power and the promise of DNA methylation markers. Nat Rev Cancer 3: 253-266, 2003.
20. Colella S, Shen L, Baggerly KA, Issa JP and Krahe R: Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 35: 146-150, 2003.
21. Tost J, Dunker J and Gut IG: Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing. Biotechniques 35: 152-156, 2003.
22. Buttin BM, Powell MA, Mutch DG, Rader JS, Herzog TJ, Gibb RK, Huettner P, Edmonston TB and Goodfellow PJ: Increased risk for hereditary nonpolyposis colorectal cancer-associated synchronous and metachronous malignancies in patients with microsatellite instability-positive endometrial carcinoma lacking MLH1 promoter methylation. Clin Cancer Res 10: 481-490, 2004.
23. Noguchi T, Tanimoto K, Shimokuni T, Ukon K, Tsujimoto H, Fukushima M, Kawahara K, Hiyama K and Nishiyama M: Aberrant methylation of DPYD promoter, DPYD expression, and cellular sensitivity to 5-fluorouracil in cancer cells. Clin Cancer Res 10: 7100-7107, 2004.